by David Cassak
For nearly a decade, one of the hottest topics in medical devices has been drug/device convergence: combining in a single...
Welcome to In Vivo
Create an account to read this article
Already a subscriber?
OrthoMEMS: Measuring What Matters in Spine
In spine, measuring the pressure or load on damaged discs can be an important diagnostic, claims OrthoMEMS, every bit as valuable as current diagnostic techniques that look only at anatomical images. Indeed, OrthoeMEMS believes it has hit upon a fundamentally important new diagnostic tool for spine surgeons, one that offers an objective alternative to current subective diagnoses and that could do for spine and orthopedics what blood pressure management did for general medicine or EKGs for cardiology.
More from Innovation
• By
Trojan Bio’s proprietary platform, based on engineered antibodies that activate the immune system to fight cancer in the same way as common viral infections, won Biomed Israel's 2025 biopharma start-up award. CEO and cofounder Anat Burkovitz said the technology is attracting investors' attention.
• By
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.
• By
Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.
• By
In Vivo sits down with Ying Tam, CSO at Acuitas Therapeutics, to discuss the company's role in delivering the first personalized CRISPR treatment to an infant and the clinical implications of new lipid nanoparticle technologies.
More from In Vivo
• By
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
• By
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.